Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems

• Published in: Seminars in cancer biology Vol. 106-107; pp. 217 - 233
• Main Authors: Lencioni, Giulia, Gregori, Alessandro, Toledo, Belén, Rebelo, Rita, Immordino, Benoît, Amrutkar, Manoj, Xavier, Cristina P.R., Kocijančič, Anja, Pandey, Deo Prakash, Perán, Macarena, Castaño, Justo P., Walsh, Naomi, Giovannetti, Elisa
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-11-2024
• Subjects: Chemoresistance; In vitro models; Organoids; Organotypic slices; Pancreatic cancer; Organotypic slices; In vitro models; Organoids; Pancreatic cancer; Chemoresistance; chemoresistance; Pancreatic ductal adenocarcinoma; in vitro models; organoids; organotypic slices
• ISSN: 1044-579X; 1096-3650; 1096-3650
• DOI: 10.1016/j.semcancer.2024.09.002

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor prognosis and rising global deaths. Late diagnosis, due to absent early symptoms and biomarkers, limits treatment mainly to chemotherapy, which soon encounters resistance. PDAC treatment innovation is hampered by its complex and heterogeneous resistant nature, including mutations in key genes and a stromal-rich, immunosuppressive tumour microenvironment. Recent studies on PDAC resistance stress the need for suitable in vitro and ex vivo models to replicate its complex molecular and microenvironmental landscape. This review summarises advances in these models, which can aid in combating chemoresistance and serve as platforms for discovering new therapeutics. Immortalised cell lines offer homogeneity, unlimited proliferation, and reproducibility, but while many gemcitabine-resistant PDAC cell lines exist, fewer models are available for resistance to other drugs. Organoids from PDAC patients show promise in mimicking tumour heterogeneity and chemosensitivity. Bioreactors, co-culture systems and organotypic slices, incorporating stromal and immune cells, are being developed to understand tumour-stroma interactions and the tumour microenvironment's role in drug resistance. Lastly, another innovative approach is three-dimensional bioprinting, which creates tissue-like structures resembling PDAC architecture, allowing for drug screening. These advanced models can guide researchers in selecting optimal in vitro tests, potentially improving therapeutic strategies and patient outcomes.